This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Friday's Health Winners & Losers

Generic drugmaker Dr. Reddy's Laboratories (RDY) fell 3.3% to $15.90 after pricing a public offering of 12.5 million American depositary shares at $16 each.

The offering, which is expected to close on Nov. 22, excludes the underwriter's over-allotment option. The company previously filed a registration and preliminary supplement prospectus with the Securities and Exchange Commission for a proposed offering of up to 13.5 million ADS's, excluding the over-allotment.

Drugmaker AMDL (ADL) jumped 8.9% to $5.12 after its China subsidiary Jade Pharmaceutical received approval from regulators there for its antibiotic levofloxacin.

The drug, which will be used to treat conditions like pneumonia and urinary tract infections, belongs to a class of drugs called fluoroquinolones. AMDL says the group represents the fastest-growing type of antibacterials in terms of revenue and is being used increasingly to treat a broad range of infections.

Genentech (DNA) gained 1.4% to $81.87 as it received an additional regulatory approval for its breast-cancer drug Herceptin.

The drug can now be used, along with a regimen of doxorubicin, cyclophosphamide and paclitaxel chemotherapy, as a treatment of early-stage, localized lymph-node positive breast cancer in patients also classified as positive for the protein known as HER2.

Pharmaceutical company Shire (SHPGY) reported positive data from clinical research on an investigational drug for attention deficit hyperactivity disorder. Still, Shire lost 0.7% to $59.83.

Based on study results on patients aged 6 to 17 years old, the drug, guanfacine extended release, significantly improved symptoms of ADHD when used by itself. Results were presented at the annual meeting of the U.S. Psychiatric and Mental Health Congress late Thursday.

Allergan (AGN) rose 3% in late trading after the U.S. approved a silicone-gel implant made by its Inamed unit. The decision ended a 14-year virtual ban on the implants despite lingering safety concerns, the Associated Press reported.

Mentor (MNT) also received approval for its implant product. Allergan rose $3.60 to $116.10. Shares in Mentor were halted.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs